Ceralasertib

Generic Name: Ceralasertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₄N_₆O_₂S

CAS Number: 1352226-88-0

Unique Ingredient Identifier: 85RE35306Z

Background: Ceralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Solid Tumours

Interventions: Drug: Ceralasertib

First Posted Date: 2020-09-25

Last Posted Date: 2024-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 54

Registration Number: NCT04564027

Locations: 🇪🇸
Research Site, Madrid, Spain

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Phase 1

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Radiation: Radiotherapy
Drug: Olaparib Oral Tablet [Lynparza]
Drug: AZD1390
Drug: Ceralasertib
Drug: AZD5305
Drug: Durvalumab

First Posted Date: 2020-09-16

Last Posted Date: 2024-02-26

Lead Sponsor: University of Leeds

Target Recruit Count: 200

Registration Number: NCT04550104

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧
Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom

and more 8 locations

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Phase 2

Recruiting

Conditions: Osteosarcoma Recurrent
Osteosarcoma

Interventions: Drug: Olaparib
Drug: Ceralasertib

First Posted Date: 2020-06-04

Last Posted Date: 2024-07-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 63

Registration Number: NCT04417062

Locations: 🇺🇸
Dana Farber Cancer Institite, Boston, Massachusetts, United States
🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸
UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology, San Francisco, California, United States

and more 1 locations

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Phase 2

Withdrawn

Conditions: Ovarian Cancer

Interventions: Drug: Olaparib
Drug: Placebo to match olaparib
Drug: Ceralasertib

First Posted Date: 2020-01-23

Last Posted Date: 2021-03-10

Lead Sponsor: AstraZeneca

Registration Number: NCT04239014

Locations: 🇪🇸
Research Site, Barcelona, Spain

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Phase 2

Recruiting

Conditions: Anatomic Stage IIIA Breast Cancer AJCC v8
Germline BRCA1 Gene Mutation
Germline BRCA2 Gene Mutation
HER2/Neu Negative
Metastatic Breast Carcinoma
Prognostic Stage III Breast Cancer AJCC v8
Advanced Breast Carcinoma
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8

Interventions: Drug: Cediranib
Drug: Ceralasertib
Drug: Olaparib

First Posted Date: 2019-09-16

Last Posted Date: 2024-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04090567

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Phase 2

Recruiting

Conditions: Gynaecological Cancers

Interventions: Drug: Ceralasertib
Drug: Olaparib
Drug: Durvalumab

First Posted Date: 2019-08-22

Last Posted Date: 2024-07-11

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 174

Registration Number: NCT04065269

Locations: 🇬🇧
Royal United Hospital, Bath, United Kingdom
🇬🇧
Western General Hospital, Edinburgh, United Kingdom
🇬🇧
The Beatson, Glasgow, United Kingdom

and more 6 locations

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Phase 2

Active, not recruiting

Conditions: Refractory Malignant Solid Neoplasm
Refractory Cholangiocarcinoma
Malignant Solid Neoplasm

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Ceralasertib
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Olaparib

First Posted Date: 2019-03-18

Last Posted Date: 2024-07-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT03878095

Locations: 🇺🇸
University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 10 locations

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Metastatic Triple-Negative Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8

Interventions: Procedure: Biopsy
Biological: Durvalumab
Drug: Capivasertib
Drug: Ceralasertib
Drug: Olaparib
Other: Quality-of-Life Assessment
Drug: Selumetinib

First Posted Date: 2019-01-11

Last Posted Date: 2024-08-13

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 132

Registration Number: NCT03801369

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2

Recruiting

Conditions: Metastatic Urothelial Carcinoma
Stage III Pancreatic Cancer
Stage III Renal Cell Cancer
Stage IV Pancreatic Cancer
Stage IV Renal Cell Cancer
Metastatic Castration-resistant Prostate Cancer
Clear Cell Renal Cell Carcinoma
Locally Advanced Pancreatic Cancer
Metastatic Renal Cell Carcinoma
Metastatic Pancreatic Cancer

Interventions: Drug: Ceralasertib
Drug: Olaparib
Drug: Durvalumab

First Posted Date: 2018-09-24

Last Posted Date: 2023-12-13

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 89

Registration Number: NCT03682289

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Adavosertib with or Without Olaparib in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma

Interventions: Drug: Adavosertib
Drug: Ceralasertib
Drug: Olaparib

First Posted Date: 2018-07-06

Last Posted Date: 2024-11-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 104

Registration Number: NCT03579316

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy